Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statements of Operations
Net Revenues	$ 216,136	$ 208,475	$ 206,547
Operating Expenses
Cost of sales (excluding depreciation and amortization)	100,610	87,157	63,154
Research and development	11,369	16,001	19,806
Selling, general, and administrative	84,294	64,986	55,843
Depreciation and amortization	47,252	44,638	44,612
Contingent consideration fair value adjustment	500	0	0
Legal settlement expense	8,750
Purified Cortrophin Gel pre-launch charges	780	11,263	6,706
Intangible asset impairment charge	2,374	446	75
Total Operating Expenses	255,929	224,491	190,196
Operating (Loss)/Income	(39,793)	(16,016)	16,351
Other Expense, net
Interest expense, net	(11,922)	(9,452)	(12,966)
Other expense, net	(4,343)	(494)	(228)
(Loss)/Income Before Benefit for Income Taxes	(56,058)	(25,962)	3,157
Benefit for income taxes	13,455	3,414	2,937
Net (Loss)/Income	(42,603)	(22,548)	6,094
Dividends on Series A convertible preferred stock	(190)
Net (Loss)/Income Allocated to Common Shares	$ (42,793)	$ (22,548)	$ 6,094
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (3.40)	$ (1.88)	$ 0.51
Diluted (Loss)/Earnings Per Share	$ (3.40)	$ (1.88)	$ 0.50
Basic Weighted-Average Shares Outstanding	12,596	11,964	11,841
Diluted Weighted-Average Shares Outstanding	12,596	11,964	12,040